MR. BRUCE ALAN DANIELS, MD
Osteopathic Medicine at Western Ave, Oklahoma City, OK
License number
Oklahoma 10948
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
4221 S Western Ave STE 4045, Oklahoma City, OK 73109
Phone
(405) 636-1166
(405) 632-8446 (Fax)
(405) 632-8446 (Fax)
Professional information
Treatment Of A Patient Suffering From Cell Surface Thrombosis Disorders Using Enhanced Absorption Of Arginine
US Patent:
2004009, May 20, 2004
Filed:
Nov 19, 2002
Appl. No.:
10/299506
Inventors:
Bruce Daniels - Oklahoma City OK, US
International Classification:
A61K031/727
US Classification:
514/056000
Abstract:
The invention as described comprises a method and composition for enhanced absorption of arginine in mammals, for the treatment of the cellular environment in cardiovascular diseases comprising the step of administering to a patient a therapeutically-effective amount of polyarginine and co-administering a therapeutically-effective amount of heparin or its functional analog or their physiologically acceptable salt. The dose of polyarginine administered to the patient is between approximately 100 mg to 6000 mg daily. Optionally, the dose of polyarginine administered to the patient is between approximately 200 mg to 1900 mg daily. Optionally, the dose of polyarginine administered to the patient is between approximately 400 mg to 1800 mg daily.
Bruce Alan Daniels, Oklahoma City OK
Specialties:
Internist
Address:
4221 S Western Ave, Oklahoma City, OK 73109
Education:
University of Oklahoma, College of Medicine - Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*
Composition For Treating A Patient Susceptible To Or Suffering From A Cardiovascular Disorder Or Disease
US Patent:
6495530, Dec 17, 2002
Filed:
Jun 8, 2001
Appl. No.:
09/851545
Inventors:
Bruce A. Daniels - Oklahoma City OK
Assignee:
Endomatrix, Inc. - Napa CA
International Classification:
A01N 4304
US Classification:
514 56, 514561, 514564, 514822, 514824
Abstract:
The present invention is directed to a composition comprising a therapeutically effective amount of exogenous heparin and arginine or physiologically acceptable salts thereof which is used in the treatment and prevention of cardiovascular diseases or disorders.
Seaweed Extract Composition For Retardation Of Cardiovascular Disorders And Preservation Of Healthy Cardiovascular Function
US Patent:
2004017, Sep 2, 2004
Filed:
Mar 5, 2004
Appl. No.:
10/795560
Inventors:
Bruce Daniels - Oklahoma City OK, US
International Classification:
A61K031/715, A61K035/80
US Classification:
424/195170, 514/054000
Abstract:
The invention of comprises of a method and composition for retardation of cardiovascular disorder in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The invention also comprises a composition and method for preserving cardiovascular health in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The seaweed is selected from the group consisting of brown algae, red algae and green algae, wherein the seaweed extract contains a polysaccharide. Optionally, the polysaccharide is Rhamnose, in approximately 70 mole %. The seaweed extract optionally also contains approximately 6.5 mole % Xylose. Optionally, Rhamnose and Xylose are present in the seaweed extract in amounts in a ratio of approximately 11 Rhamnose to 1 Xylose. Optionally, the seaweed extract is mixed with food stuffs such as cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.
Composition And Method For Treating A Patient Susceptible To Or Suffering From A Cardiovascular Disorder Or Disease
US Patent:
6255296, Jul 3, 2001
Filed:
Apr 30, 1999
Appl. No.:
9/302690
Inventors:
Bruce A. Daniels - Oklahoma City OK
Assignee:
EndoMatrix, Inc. - Napa CA
International Classification:
A01N 4304
US Classification:
514 56
Abstract:
A method for inhibiting the effects of cardiovascular disorders and diseases in a host susceptible to or suffering from a cardiovascular disorder or disease comprising administering to the host, a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a therapeutically effective amount of a second substance characterized as simulating an arginine-like effect; and a formulation for use in treating a host susceptible to or suffering from the effects of cardiovascular disorders and diseases comprising a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a second substance characterized an simulating an arginine-like effect, an described.
Seaweed Extract Composition For Treatment Of Diabetes And Diabetic Complications
US Patent:
2007008, Apr 12, 2007
Filed:
Dec 7, 2006
Appl. No.:
11/635882
Inventors:
Bruce Daniels - Oklahoma City OK, US
International Classification:
A61K 31/715, A61K 36/02
US Classification:
514054000, 424195170
Abstract:
A method and composition is described for prevention or treatment of Type II Diabetes Mellitus and its complications comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The seaweed is selected from the group consisting of brown algae, red algae and green algae, wherein the seaweed extract contains a polysaccharide. Optionally, the polysaccharide is Rhamnose, in approximately 63-78 mole %. The seaweed extract optionally also contains approximately 6.5-9.2 mole % Xylose. Optionally, Rhamnose and Xylose are present in the seaweed extract in amounts in a ratio of approximately 12 Rhamnose to 1 Xylose and 8 Rhamnose to 1 Xylose. Preferably, the Rhamnose (algopolysaccharide) is sulfinated. Optionally, the seaweed extract is mixed with food stuffs such as cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.
Method Of Predicting The Structural Integrity Of Mamalian Tissue
US Patent:
2004011, Jun 17, 2004
Filed:
Mar 7, 2003
Appl. No.:
10/383888
Inventors:
Bruce Daniels - Oklahoma City OK, US
International Classification:
A61K031/727, G01N033/53
US Classification:
514/056000, 435/007100
Abstract:
The invention claimed is a method of predicting the structural integrity of a mammalian tissue comprising the steps of measuring an amount of a heparanoid-like substance in a mammalian bodily excretion then referring to a predictive chart showing a correlation between the amount of the heparanoid-like substance in the mammalian bodily excretion in relation to an amount of the heparanoid-like substance in said mammalian tissue and then predicting the amount of heparanoid-like substance in said mammalian tissue from the amount of heparanoid-like substance measured in the mammalian bodily excretion.
Therapeutic Sulfated Polysaccharides, Compositions Thereof, And Methods For Treating Patients
US Patent:
2014004, Feb 13, 2014
Filed:
Sep 21, 2012
Appl. No.:
13/624742
Inventors:
Bruce A. Daniels - Oklahoma City OK, US
International Classification:
A61K 31/737, G01N 33/50
US Classification:
536118, 435 613
Abstract:
Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.
Therapeutic Sulfated Polysaccharides, Compositions Thereof, And Methods For Treating Patients
US Patent:
2013027, Oct 17, 2013
Filed:
Oct 5, 2012
Appl. No.:
13/646496
Inventors:
Bruce A. Daniels - Oklahoma City OK, US
International Classification:
A61K 31/737, G01N 33/50
US Classification:
42419517, 536118, 435 29, 514 54
Abstract:
Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.
Method For The Treatment Of Diabetes
US Patent:
7022682, Apr 4, 2006
Filed:
May 14, 2003
Appl. No.:
10/438088
Inventors:
Bruce Alan Daniels - Oklahoma City OK, US
Assignee:
Endomatrix, Inc. - Santarosa CA
International Classification:
A61K 31/715
US Classification:
514 53, 514 54, 514866, 536122
Abstract:
The present invention provides for a method for treatment and prevention of Type II Diabetes Mellitus and its complications comprising the step of administering to a patient a therapeutically-effective amount of Rhamnan Sulphate, its functional analogs, or its physiologically acceptable salts, in therapeutic proportions. Anticoagulation activity in the blood plasma of a patient is not appreciably increased.